Cargando…

Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases

Chinese medicine is a national treasure that has been passed down for thousands of years in China. According to the statistics of the World Health Organization, there are currently four billion people in the world who use Chinese medicine to treat diseases, accounting for 80% of the world’s total po...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yong-Zhi, Jiang, Ying-Nan, Li, Yi-Fang, Kurihara, Hiroshi, Dai, Yi, He, Rong-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987446/
https://www.ncbi.nlm.nih.gov/pubmed/32038243
http://dx.doi.org/10.3389/fphar.2019.01564
_version_ 1783492142847492096
author Guo, Yong-Zhi
Jiang, Ying-Nan
Li, Yi-Fang
Kurihara, Hiroshi
Dai, Yi
He, Rong-Rong
author_facet Guo, Yong-Zhi
Jiang, Ying-Nan
Li, Yi-Fang
Kurihara, Hiroshi
Dai, Yi
He, Rong-Rong
author_sort Guo, Yong-Zhi
collection PubMed
description Chinese medicine is a national treasure that has been passed down for thousands of years in China. According to the statistics of the World Health Organization, there are currently four billion people in the world who use Chinese medicine to treat diseases, accounting for 80% of the world’s total population. However, the obscurity of its theory, its unmanageable quality, its complex compositions, and the unknown effective substances and mechanisms are great obstacles to the internationalization of Chinese medicine. Here, we propose a new strategy for the development of Chinese medicine: the clinical prescription (C)-protein (P)-small-molecule (S)-disease (D) strategy, namely the CPSD strategy. The strategy uses clinical prescriptions as the source of medicine and uses computer simulation technology to find small-molecule drugs targeting therapeutic proteins for treating specific diseases so as to deepen awareness of the value of Chinese medicine. At the same time, this article takes cardiovascular drug development as an example to introduce the application of CPSD, which will be instrumental in the further development, modernization, and internationalization of Chinese medicine.
format Online
Article
Text
id pubmed-6987446
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69874462020-02-07 Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases Guo, Yong-Zhi Jiang, Ying-Nan Li, Yi-Fang Kurihara, Hiroshi Dai, Yi He, Rong-Rong Front Pharmacol Pharmacology Chinese medicine is a national treasure that has been passed down for thousands of years in China. According to the statistics of the World Health Organization, there are currently four billion people in the world who use Chinese medicine to treat diseases, accounting for 80% of the world’s total population. However, the obscurity of its theory, its unmanageable quality, its complex compositions, and the unknown effective substances and mechanisms are great obstacles to the internationalization of Chinese medicine. Here, we propose a new strategy for the development of Chinese medicine: the clinical prescription (C)-protein (P)-small-molecule (S)-disease (D) strategy, namely the CPSD strategy. The strategy uses clinical prescriptions as the source of medicine and uses computer simulation technology to find small-molecule drugs targeting therapeutic proteins for treating specific diseases so as to deepen awareness of the value of Chinese medicine. At the same time, this article takes cardiovascular drug development as an example to introduce the application of CPSD, which will be instrumental in the further development, modernization, and internationalization of Chinese medicine. Frontiers Media S.A. 2020-01-22 /pmc/articles/PMC6987446/ /pubmed/32038243 http://dx.doi.org/10.3389/fphar.2019.01564 Text en Copyright © 2020 Guo, Jiang, Li, Kurihara, Dai and He http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Guo, Yong-Zhi
Jiang, Ying-Nan
Li, Yi-Fang
Kurihara, Hiroshi
Dai, Yi
He, Rong-Rong
Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases
title Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases
title_full Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases
title_fullStr Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases
title_full_unstemmed Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases
title_short Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases
title_sort clinical prescription-protein-small molecule-disease strategy (cpsd), a new strategy for chinese medicine development: a case study in cardiovascular diseases
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987446/
https://www.ncbi.nlm.nih.gov/pubmed/32038243
http://dx.doi.org/10.3389/fphar.2019.01564
work_keys_str_mv AT guoyongzhi clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases
AT jiangyingnan clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases
AT liyifang clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases
AT kuriharahiroshi clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases
AT daiyi clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases
AT herongrong clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases